82632-77-7

Basic information

• Product Name: 4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE
• Synonyms: 4-(4-chlorophenyl)-5-methyl-2-thiazolamine;4-(4-CHLOROPHENYL)-5-METHYL-1,3-THIAZOL-2-AMINE;4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE;4-(4-CHLOROPHENY)-5-METHYLTHIAZOL-2-YLAMINE;CHEMBRDG-BB 3007469;4-(4-chlorophenyl)-5-methyl-1,3-thiazol-2-amine(SALTDATA: FREE);4-(4-Chlorophenyl)-5-Methylthiazol-2-aMine
• CAS NO: 82632-77-7
• Molecular Formula: C₁₀H₉ClN₂S
• Molecular Weight: 224.71
• Mol File: 82632-77-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 144-145℃ (hexane ethyl acetate )
• Boiling Point: 376.6 °C at 760 mmHg
• Flash Point: 181.6 °C
• Appearance: /
• Density: 1.338 g/cm³
• Vapor Pressure: 7.14E-06mmHg at 25°C
• Refractive Index: 1.65
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE(82632-77-7)
• EPA Substance Registry System: 4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE(82632-77-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 82632-77-7(Hazardous Substances Data)

Usage

General Description

4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE is a chemical compound with the molecular formula C11H10ClN3S. It is a thiazole derivative, which is a type of organic compound containing a five-membered ring with sulfur and nitrogen atoms. 4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE is a potent inhibitor of the enzyme glycogen synthase kinase-3 (GSK-3), which plays a role in various cellular processes such as metabolism, cell differentiation, and apoptosis. GSK-3 inhibitors have shown potential for the treatment of various diseases, including cancer, neurodegenerative disorders, and diabetes. 4-(4-CHLORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE may have potential therapeutic applications in the future due to its ability to modulate GSK-3 activity.

InChI:InChI=1/C10H9ClN2S/c1-6-9(13-10(12)14-6)7-2-4-8(11)5-3-7/h2-5H,1H3,(H2,12,13)

Upstream product

• 6285-05-8 4'-chloropropiophenone 
• 104-88-1 4-chlorobenzaldehyde 
• 13856-85-4 1-(4-chlorophenyl)-1-propanol 
• 877-37-2 2-bromo-1-(4-chlorophenyl)-1-propanone 
• 333-20-0 potassium thioacyanate 
• 17356-08-0 thiourea 

Downstream Products

• 438215-14-6 4-((4-(4-chlorophenyl)-5-methylthiazol-2-yl)amino)-4-oxobutanoic acid 
• 1398574-80-5 C₁₅H₁₅ClN₂O₃S 
• 27225-23-6 4-(4-chloro-phenyl)-2-fluoro-5-methyl-thiazole 
• 130831-35-5 4-amino-N-[4-(4-chloro-phenyl)-5-methyl-thiazol-2-yl]-benzenesulfonamide 
• 103096-90-8 4-acetylamino-N-[4-(4-chloro-phenyl)-5-methyl-thiazol-2-yl]-benzenesulfonamide 

Relevant articles and documents

Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools

The most common CF mutation, F508del, impairs the processing and gating of CFTR protein. This deletion results in the improper folding of the protein and its degradation before it reaches the plasma membrane of epithelial cells. Present correctors, like VX809 only induce a partial rescue of the mutant protein. Our previous studies reported a class of compounds, called aminoarylthiazoles (AATs), featuring an interesting activity as correctors. Some of them show additive effect with VX809 indicating a different mechanism of action. In an attempt to construct more interesting molecules, it was thought to generate chemically hybrid compounds, blending a portion of VX809 merged to the thiazole scaffold. This approach was guided by the development of QSAR analyses, which were performed based on the F508del correctors so far disclosed in the literature. This strategy was aimed at exploring the key requirements turning in the corrector ability of the collected derivatives and allowed us to derive a predictive model guiding for the synthesis of novel hybrids as promising correctors. The new molecules were tested in functional and biochemical assays on bronchial CFBE41o-cells expressing F508del-CFTR showing a promising corrector activity.

Synthesis and antimicrobial activities of some novel 2,3-substituted-1,3-thiazolidin-4-ones derived from 2-amino-1,3-thiazole

New 2,3-substituted-1,3-thiazolidin-4-one (6a-f) were prepared by cyclocondensation of 2-[6-(4-chlorobenzyloxy)-2-naphthyliden]-4-(4-substituted phenyl)-5-methyl-1,3-thiazole (5a-f) and mercaptoacetic acid in benzene. The synthesized compounds were charac

PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS

The present invention is related to novel pyrimidinedione-fused heterocyclic compounds as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.